- 7. The formulation of claim 1, wherein the 15-keto-prostaglandin compound is a 15-keto-prostaglandin E compound.
- 8. The formulation of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin  $\rm E_1.$
- **9**. The formulation of claim **1**, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-18S-methyl-prostaglandin  $E_1$ .
- 10. The formulation of claim 1, wherein the sugar alcohol is selected from the group consisting of sorbitol, maltitol, sugar alcohol solution derived from corn starch, hydrogenated maltose syrup and a mixture thereof.
- 11. The formulation of claim 1, wherein the sugar alcohol  $_{15}$  comprises sorbitol and sorbitan as its major component.
- 12. The formulation of claim 1, wherein the pharmaceutically acceptable vehicle is a fatty acid ester.
- 13. The formulation of claim 1, wherein the pharmaceutically acceptable vehicle is a polyol.
- 14. The formulation of claim 1, wherein the pharmaceutically acceptable vehicle is glycerin or propylene glycol.
- 15. The formulation of claim 10, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin  $\rm E_1$ .
- 16. The formulation of claim 11, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin  $\rm E_1$ .
- 17. The formulation of claim 12, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin  $\rm E_1$ .
- 18. The formulation of claim 13, wherein the 15-keto-  $_{\rm 35}$  prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin  $\rm E_{\rm 1}$  .
- **19**. The formulation of claim **14**, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin  $\rm E_1$ .
- 20. The formulation of claim 1, wherein the sugar alcohol comprises sorbitol,

wherein the pharmaceutically acceptable vehicle comprises a fatty acid ester, and

wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E<sub>1</sub>.

16

21. A soft gelatin capsule formulation comprising: a soft gelatin capsule shell comprising gelatin and a sugar alcohol as a plasticizer, and a mixture comprising

and a pharmaceutically acceptable vehicle, which is filled in the shell.

wherein the pharmaceutically acceptable vehicle is a fatty acid ester or a polyol.

22. A soft gelatin capsule formulation comprising: a soft gelatin capsule shell comprising gelatin and a sugar alcohol as a plasticizer, and a mixture comprising

and a pharmaceutically acceptable vehicle, which is filled in  $^{40}\,$  the shell,

wherein the pharmaceutically acceptable vehicle is a fatty acid ester or a polyol.

23. The formulation of claim 1, wherein M is a group other than hydrogen.

\* \* \* \* \*